相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunotherapy and targeted therapy combinations in metastatic breast cancer
Francisco J. Esteva et al.
LANCET ONCOLOGY (2019)
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer
Jieun Lee et al.
CANCER RESEARCH AND TREATMENT (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
Elisabeth Specht Stovgaard et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer
Thomas A. Adams et al.
MODERN PATHOLOGY (2018)
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
Nobumoto Tomioka et al.
BREAST CANCER (2018)
An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer
Lauren E. McLemore et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer
Seo Hee Choi et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications
Jing He et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
Ming Li et al.
BMC CANCER (2018)
The combined presence of CD20+B cells and PD-L1+tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome
H. Arias-Pulido et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene
Yanchun Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer
Xinyu Ren et al.
CANCER BIOLOGY & THERAPY (2018)
The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis
Guangzhi Ma et al.
CLINICA CHIMICA ACTA (2018)
Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
Yunxuan Wang et al.
JOURNAL OF BREAST CANCER (2018)
Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters
Fei Li et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2018)
Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
Yuka Asano et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
USCAP 2018 Abstracts: Breast Pathology (121–337)
LABORATORY INVESTIGATION (2018)
Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial
Vasiliki Pelekanou et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
Tingting Zhou et al.
ANTI-CANCER DRUGS (2018)
PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer
Yanjun Hou et al.
BREAST JOURNAL (2018)
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
Marcelo Sobral-Leite et al.
ONCOIMMUNOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
Michael T. Barrett et al.
BREAST CANCER RESEARCH (2018)
Triple negative breast cancer - prognostic role of immune-related factors: a systematic review
Elisabeth Specht Stovgaard et al.
ACTA ONCOLOGICA (2018)
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
Upasana Joneja et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
Jamaal A. Rehman et al.
MODERN PATHOLOGY (2017)
Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer
Laurence Buisseret et al.
ONCOIMMUNOLOGY (2017)
PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy
Sheng Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
Gerardo Botti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer
Antonio Polonia et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
Prognostic significance of PD-L1 in solid tumor An updated meta-analysis
Qianqian Wang et al.
MEDICINE (2017)
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast
Elizabeth D. Thompson et al.
MODERN PATHOLOGY (2017)
PD-L1 and intratumoral immune response in breast cancer
Zhi-Qiang Wang et al.
ONCOTARGET (2017)
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
Minghui Zhang et al.
ONCOTARGET (2017)
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
Hitomi Mori et al.
ONCOTARGET (2017)
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Bruna Cerbelli et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma
Jian Lou et al.
OPEN MEDICINE (2017)
Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis
Tiancheng Zhao et al.
PLOS ONE (2017)
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
Ahrong Kim et al.
SCIENTIFIC REPORTS (2017)
Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer
Mina Okabe et al.
CANCER SCIENCE (2017)
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis
Hye Min Kim et al.
BMC CANCER (2017)
Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis
Changjun Wang et al.
BREAST JOURNAL (2017)
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Atsuko Kitano et al.
ESMO OPEN (2017)
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages An Assessment of 245 Primary and 40 Metastatic Tumors
Erik A. Dill et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
PD-L1 expression and tumor infiltrating PD-1+lymphocytes associated with outcome in HER2+breast cancer patients
Julia Y. S. Tsang et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
Xiaoxian Li et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer
In Hae Park et al.
CLINICAL BREAST CANCER (2016)
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
Rhiannon K. Beckers et al.
HISTOPATHOLOGY (2016)
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Ashley Cimino-Mathews et al.
HUMAN PATHOLOGY (2016)
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Mauricio Z. Baptista et al.
HUMAN PATHOLOGY (2016)
Expression of Programmed Death Receptor Ligand 1 with High Tumor Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer
Sang Byung Bae et al.
JOURNAL OF BREAST CANCER (2016)
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Woo Young Sun et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis
Yawen Guo et al.
PLOS ONE (2016)
Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis
Xue Li et al.
TARGETED ONCOLOGY (2016)
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient
Zhenhua Li et al.
JOURNAL OF CANCER (2016)
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Lei Guo et al.
SPRINGERPLUS (2016)
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
Hye Ryun Kim et al.
SCIENTIFIC REPORTS (2016)
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H. R. Ali et al.
ANNALS OF ONCOLOGY (2015)
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
Tao Qin et al.
ONCOTARGET (2015)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
The B7 family of immunoregulatory receptors: A comparative and evolutionary perspective
John D. Hansen et al.
MOLECULAR IMMUNOLOGY (2009)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
分享论文
